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Abstract
Background: There are no randomised and properly blinded trials directly comparing one PDE-
5 inhibitor with another in a normal home setting. Valid indirect comparisons with a common
comparator must examine equivalent doses, similar duration, similar populations, with the same
outcomes reported in the same way.
Methods:  Published randomised, double-blind trials of oral PDE-5 inhibitors for erectile
dysfunction were sought from reference lists in previous reviews and electronic searching. Analyses
of efficacy and harm were carried out for each treatment, and results compared where there was
a common comparator and consistency of outcome reporting, using equivalent doses.
Results: Analysis was limited by differential reporting of outcomes. Sildenafil trials were clinically
and geographically more diverse. Tadalafil and vardenafil trials tended to use enriched enrolment.
Using all trials, the three interventions were similar for consistently reported efficacy outcomes.
Rates of successful intercourse for sildenafil, tadalafil and vardenafil were 65%, 62%, and 59%, with
placebo rates of 23–28%. The rates of improved erections were 76%, 75% and 71%, respectively,
with placebo rates of 22–24%, and NNTs of 1.9 or 2.0. Reporting of withdrawals was less
consistent, but all-cause withdrawals for sildenafil, tadalafil and vardenafil were 8% 13% and 20%.
All three drugs were well tolerated, with headache being the most commonly reported event at
13–17%. There were few serious adverse events.
Conclusion: There were differences between trials in outcomes reported, limiting comparisons,
and the most useful outcomes were not reported. For common outcomes there was similar
efficacy between PDE-5 inhibitors.
Background
Comparing different interventions for the same condition
is often difficult. Large direct comparisons are uncom-
mon, and usually represent only a fraction of the total ran-
domised trial data available. Instead we often have large
numbers of randomised trials comparing different inter-
ventions with the same or similar comparators, like pla-
cebo or an active comparator. These may be direct
comparisons, but not the direct comparisons we want.
Indirect comparison of interventions using a common
comparator is a valuable alternative because it uses more
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of the published data [1], and has been done before for
analgesics in acute pain [2] and migraine treatments [3].
Even this approach can be devalued because clinical trials
in published papers are not consistent in the outcomes
they report, or the way they report them [4].
The ideal should be to compare interventions of equiva-
lent intensities or dose, in the same condition, at similar
disease severity, using the same outcomes properly
reported, over the same period of time. In this study we
use the example of published studies of phosphodieste-
rase-5 (PDE-5) inhibitors for male erectile dysfunction to
examine the problems of comparing therapies. PDE-5
inhibitors were chosen because they have been intro-
duced within the past decade, by three different pharma-
ceutical companies, and in an era of good clinical trial
practice. There are no good quality trials directly compar-
ing PDE-5 inhibitors at equivalent doses.
Methods
We sought randomised trials of three PDE-5 inhibitors
(sildenafil, tadalafil, vardenafil), with placebo or active
comparator, in men with erectile dysfunction of any cau-
sation. Previous systematic reviews [5-9] were used to
source trials or trial data, supplemented by electronic
searches of PubMed (to June 2005) and the Cochrane
Library (issue 1, 2005) using drug names and ran-
domis(z)ed trial.
For inclusion a trial had to be randomised and double
blind, use one of the three oral PDE-5 inhibitors in men
with erectile dysfunction, be conducted in the home set-
ting, last three weeks or longer, have a minimum of 10
men per group, and report useful information on efficacy
or adverse events. Abstracts were read, and potentially use-
ful reports retrieved in full paper copy. Decisions on inclu-
sion or exclusion were made by consensus. No
information was taken from posters or abstracts, and stud-
ies were read carefully to avoid including duplicate mate-
rial. Studies were scored for reporting quality using a
common method [10] utilising reporting of randomisa-
tion, blinding and withdrawals. The maximum score pos-
sible was 5 points, and no study could be included with
fewer than 2 points.
Information extracted from studies included the number
of men studied, the cause of erectile dysfunction, and
country where the study was performed. Any type of out-
come was initially extracted from the studies, in continu-
ous or dichotomous form, and with any dispersion
information available. Outcomes could be reported in
tables, in graphs, or in text. The following outcomes were
sought particularly:
Efficacy
• Improved erections ("Has the treatment you have been
taking over the past four weeks improved your erec-
tions?")
• Erections per week
• Successful attempts at sexual intercourse
• More than 60% or 75% successful
• More than 40% successful
• Final score or change from baseline on question 3 of the
International Index of Erectile Function (IIEF) [11] ("Over
the past four weeks, when you attempted sexual inter-
course, how often were you able to penetrate your part-
ner?")
• Final score or change from baseline on question 4 of the
IIEF ("Over the past four weeks, during sexual intercourse,
how often were you able to maintain your erection after
you had penetrated your partner?")
• Final score or change from baseline on the IIEF erectile
function domain score
• Normal erectile function at end of study (IIEF total score
of 22 or more out of 30)
Withdrawal
• All cause
• Lack of efficacy
• Adverse event
Adverse events
• Patient with at least one adverse event
• Severe (using standard adverse event definitions)
• Serious (using standard adverse event definitions)
• Treatment-related
• Headache
• Dyspepsia
• Flushing
• Nasal congestion or rhinitis
• Visual disturbanceBMC Urology 2005, 5:18 http://www.biomedcentral.com/1471-2490/5/18
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• Myalgia and/or back pain
• Other individual adverse events
Other information sought from trials was the relationship
between taking a dose of PDE-5 inhibitor and time of
attempted or successful sexual intercourse. The aim was to
examine evidence for differences between speed of onset
or duration of effect.
Guidelines for quality of reporting of meta-analyses were
followed where appropriate [12]. The prior intention was
to pool data where there was clinical homogeneity, with
similar patients, dose, duration, outcomes, and compara-
tors, but not where numbers of events were small, and
random chance could dominate effects of treatment [13].
Clinical trials of PDE-5 inhibitors use both fixed dosing
and dose optimisation, in which doses can be increased or
decreased within set levels to balance improved efficacy
with adverse events. We noted that most dose optimisa-
tion schedule studies reported that the majority of
patients were on the top dose at the end of the study. We
therefore chose to include dose optimisation trials with
trials of the top fixed dose. We analysed only licensed
doses, as listed in the British National Formulary.
Our intent was to minimise subgroup analysis. There was
little prior information that erectile dysfunction from par-
ticular causes responds differently to treatment. We used
the intention to treat definitions used in the studies (usu-
ally number of patients randomised, receiving at least one
dose of trial drug, and with at least one post randomisa-
tion measurement). When that information was not avail-
able we used the numbers of men used as denominators
in the trial reports.
Mean results for continuous data were calculated and
weighted by the number of men in treatment groups.
Homogeneity tests and funnel plots, though commonly
used in meta-analysis, were not used here because they
have been found to be unreliable [14-16]. Instead clinical
homogeneity was examined graphically [17]. Relative
benefit (or risk) and number-needed-to-treat (or harm)
were calculated with 95% confidence intervals. Relative
risk was calculated using a fixed effects model [18], with
no statistically significant difference between treatments
assumed when the 95% confidence intervals included
unity. We added 0.5 to treatment and comparator arms of
trials in which at least one arm had no events. Number-
needed-to-treat (or harm) was calculated by the method
of Cook and Sackett [19] using the pooled number of
observations only when there was a statistically significant
difference of relative benefit or risk (where the confidence
interval did not include 1).
The following terms were used to describe outcomes in
terms of benefit, harm or prevention of harm:
• When significantly more beneficial events occurred with
PDE-5 inhibitor than with placebo we used the term the
number-needed-to-treat to produce one event (NNT).
• When significantly fewer withdrawals or adverse events
occurred with PDE-5 inhibitor than with placebo we used
the term the number-needed-to-treat to prevent one event
(NNTp).
• When significantly more adverse events occurred with
PDE-5 inhibitor compared with placebo we used the term
the number-needed-to-harm to cause one event (NNH).
The format for presentation of trial details and results was
decided prospectively, to show the number of trials and
patients on which calculations were based, and either the
number of events, or event rates, together with relative risk
or benefit and NNT. In this way absolute as well as relative
differences would be apparent. Summary data would be
Table 1: PDE-5 inhibitor trials by condition (percent of total)
Condition Sildenafil Tadalafil Vardenafil
Mixed aetiology 67 75 73
Diabetes 14 11 13
Prostatectomy 0.0 15 13
Depression 5.7 0.0 0.0
Spinal cord injury 5.3 0.0 0.0
Multiple sclerosis 3.1 0.0 0.0
Coronary heart disease 2.1 0.0 0.0
Radiotherapy for prostate cancer 1.7 0.0 0.0
Renal failure and haemodialysis 1.0 0.0 0.0
Rectal surgery 0.5 0.0 0.0
Spina bifida 0.5 0.0 0.0BMC Urology 2005, 5:18 http://www.biomedcentral.com/1471-2490/5/18
Page 4 of 16
(page number not for citation purposes)
shown only where it was from two or more studies, with
more than 200 patients, and more than 30 events. No for-
mal testing of difference was planned.
Results
There were 35 included studies using sildenafil [20-54],
treating 7135 men with a mixture of conditions causing
erectile dysfunction (Table 1); one study [40] was ana-
lysed as two trials. Of the men, 3279 received placebo and
3856 sildenafil, of whom all but 90 took licensed doses of
25 to 100 mg. Optimised dosing with 25–100 mg was
most used (2546 men), followed by 100 mg (506) or 50
mg (370). All were placebo-controlled with no active
comparator. Quality scores were high, 11 trials scoring 5
of 5 points, 17 scoring 4 points, six 3 points, and two 2
points. One further study [55] used a withdrawal model
after successful treatment, and information from the 205
men in this study was not included in this analysis.
There were eight included studies using tadalafil [56-63],
treating 2071 men with a mixture of conditions causing
erectile dysfunction (Table 1). Of these, 632 received pla-
cebo and 1439 tadalafil, of whom all but 35 took licensed
doses of 5 to 20 mg. All were placebo-controlled with no
active comparator. Doses of 20 mg (1258) or 10 mg (109)
were most frequent, with no dose-optimised studies.
Quality scores were high, two trials scoring 5 of 5 points,
one scoring 4 points, four 3 points, and one 2 points. One
further trial [64] was a population dose-response study
and was not included.
There were seven included studies with vardenafil [65-
71], treating 3374 men with a mixture of conditions caus-
ing erectile dysfunction (Table 1). Of these, 1067 received
placebo and 2307 vardenafil, all at licensed doses of 5 to
20 mg. Fixed dosing was most used with 10 mg (809) or
20 mg (698), together with some dose optimised studies
of 5–20 mg (382). All were placebo-controlled with no
active comparator. Quality scores were high, three trials
scoring 5 of 5 points, and four scoring 4 points. One fur-
ther trial [72] had no placebo group and enriched enrol-
ment and was not included.
Details of the included studies are in additional files 1:
conditions, country, treatment, dose, duration and qual-
ity score [see Additional file 1]; 2: efficacy outcomes, with-
drawals, and adverse events (patients with any adverse
event, and severe, serious and treatment-related adverse
events) [see Additional file 2]; and 3: details of particular
adverse events [see Additional file 3].
Study reporting
All studies provided background information on partici-
pants. Typically men had to have a history of erectile dys-
function of at least three to six months, and the average
age of men was generally in the mid 50s or older. Some
studies had an enriched enrolment in which previous
unsuccessful treatment with a PDE-5 inhibitor was an
exclusion criterion. This applied to five of eight tadalafil
studies, and six of seven vardenafil studies [see Additional
file 1], but none of the sildenafil studies. One vardenafil
study [70] included only men previously unresponsive to
sildenafil.
Studies almost always documented that PDE-5 inhibitor
was to be taken as needed to a maximum of one treatment
a day, with the additional instruction for sildenafil and
vardenafil that the dose be taken about an hour before
intercourse. Some studies gave information on the
number of doses actually taken. Many of the dose opti-
mised studies reported the proportion of men on maxi-
mum dose at the end of the study, which was always over
50%, and typically 60–80%. Trial duration was typically
four to 12 weeks, with 12 weeks the commonest duration.
A number of different conditions causing erectile dysfunc-
tion were studied (Table 1). All three PDE-5 inhibitors
had a similar proportion of men with mixed aetiology
(organic, psychogenic, or mixed) and diabetes. Erectile
dysfunction after prostatectomy was studied for tadalafil
and vardenafil, but not sildenafil; none of a number of
studies of sildenafil after prostatectomy could be
included, mainly because they were not randomised. With
sildenafil, a variety of additional conditions were studied,
including depression, spinal cord injuries, multiple scle-
Table 2: Patient numbers in PDE-5 inhibitor trials (by world region)
Region Sildenafil Tadalafil Vardenafil
Europe 2040 839 309
North America 2486 546 1658
South America 631 0 0
Asia 1026 0 279
Africa 254 0 0
Australia 63 0 0
World 0 0 448
Europe and North America 217 651 580
Europe and Australia 349 0 0BMC Urology 2005, 5:18 http://www.biomedcentral.com/1471-2490/5/18
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rosis, coronary heart disease, radiotherapy for prostate
cancer, renal failure and haemodialysis patients, rectal
surgery and spina bifida.
Many studies were multicentre, often performed in differ-
ent countries (Table 2). Europe, North America and Aus-
tralia accounted for most of the men in the studies for
tadalafil and vardenafil. Sildenafil studies in addition
were reported from South America, Asia, and Africa.
The percentage of men in trials about whom information
was provided for various outcomes is shown in Table 3.
Reporting of efficacy was mixed. Almost all trials used the
outcome of improved erections, and most used the final
score or change from baseline in the erectile function
domain of the IIEF. Also commonly reported was the per-
centage of attempts at sexual intercourse that were suc-
cessful, usually as an average. Final scores on questions 3
and 4 of the IIEF, or change from baseline, were reported
in over 90% of sildenafil trials, but in less than 30% of tri-
als of tadalafil or vardenafil.
Study withdrawal for any cause, or because of lack of effi-
cacy or adverse events was commonly reported. The
reporting of men with any adverse event, with severe or
serious adverse events according to recognised adverse
event reporting criteria, or those adverse events consid-
ered treatment related by investigators, was not consist-
ent. Most studies reported specific adverse events only if
they occurred in a certain proportion of men, usually
between 2% and 5%. As a consequence, some adverse
events (headache, dyspepsia, flushing, nasal congestion
or rhinitis, or visual disturbance) were consistently
reported while others were not.
Analysis
The first stage was a detailed analysis of outcomes for each
intervention, followed by a comparison between inter-
Table 3: Percentage of men in all trials for whom an outcome is reported
Outcome Slidenafil n = 7077 Tadalafil n = 2036 Vardenafil n = 3274
Efficacy
Improved erections 83 83 100
Mean # erections/week 20 0 0
Successful attempts at SI 47 72 100
More than 60/75% successful 10 0 18
More than 40% successful 0 0 0
Final score IIEF Q3 94 27 26
Mean change IIEF Q3 91 27 26
Final score IIEF Q4 94 27 26
Mean change IIEF Q4 91 27 26
Final score EF Domain 56 72 100
Mean change EF Domain 54 83 77
Normal EF at endpoint 8 56 14
Withdrawals
All-cause 83 65 69
Lack of efficacy 81 72 82
Adverse event 90 83 100
Adverse events
Men with any adverse event 42 40 18
Severe 27 25 35
Serious 38 83 78
Treatment related 55 3 43
Headache 99 90 86
Dyspepsia 79 71 73
Flushing 99 73 73
Nasal congestion/rhinitis 64 35 73
Visual disturbances 89 46 55
Back pain 13 73 9
Myalgia/increased CPK 16 60 18
Flu syndrome 17 30 34
CV events 24 27 33
Limb pain 10 11 0
Fatigue 3 15 0
Priapism 29 0 0
Nausea 14 0 0BMC Urology 2005, 5:18 http://www.biomedcentral.com/1471-2490/5/18
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ventions where there was sufficient information to make
the comparison valid. To make comparisons between dif-
ferent interventions, similar outcomes and similar inten-
sities of intervention have to be compared in similar
patients. Only those outcomes with a reasonably high and
consistent reporting frequency were available for compar-
ison.
Individual analyses
Sildenafil
Results for continuous efficacy outcomes for sildenafil are
shown in Table 4. Average results for percentage successful
attempts at intercourse, for the erectile function domain
score, and for the change in the erectile function domain
score from baseline were consistently available for the
optimised dose, and for some trials with fixed dose. Com-
bined data for 50 mg and 100 mg fixed doses and dose
optimised regimens are reported (50/100).
Results for dichotomous variables of efficacy and adverse
events for sildenafil are shown in Table 5. Here data were
available for most studies. The analysis combined dose-
optimised regimens with 100 mg fixed dose, since the
bulk of patients on dose-optimised regimens were on 100
mg.
For efficacy, the NNT for improved erections was the same
at 1.9 for all doses above 25 mg, demonstrating compara-
ble efficacy and justifying combining those doses. Com-
bining all information on 50 mg and 100 mg with dose
optimised regimens (5467 men), improved erections
were reported in 76% of men on sildenafil and 23% on
placebo (Figure 1). The NNT was 1.9 (95% confidence
interval 1.8 to 2.0).
Combining all information on 50 mg and 100 mg with
dose optimised regimens, both all cause and lack of effi-
cacy withdrawals reported in about 5600 men, were lower
with sildenafil than with placebo, with NNTp values of 23
(17 to 37) and 25 (21 to 34) respectively. Adverse event
withdrawals were higher with sildenafil than with pla-
cebo, with an NNH of 120 (67 to 560).
Table 4: Summary of continuous outcomes for sildenafil, tadalafil and vardenafil
Sildenafil
Number of
Outcome Dose Trials Patients Weighted mean
Percentage successful attempts placebo 16 1448 23
50/100 16 1589 65
Erectile function domain score placebo 23 1870 14.0
50/100 23 1893 22.0
Erectile function domain change placebo 23 1870 2.7
50/100 23 1893 10.1
Tadalafil
Number of
Outcome Dose Trials Patients Weighted mean
Percentage successful attempts placebo 6 388 26
10/20 6 1047 62
Erectile function domain score placebo 6 388 14.6
10/20 6 1047 22.3
Erectile function domain change placebo 7 459 0.8
10/20 7 1192 8.4
Vardenafil
Number of
Outcome Dose Trials Patients Weighted mean
Percentage successful attempts placebo 7 996 28
10/20 7 1789 59
Erectile function domain score placebo 7 996 14.0
10/20 7 1789 20.1
Erectile function domain change placebo 7 996 1.3
10/20 7 1344 8.3BMC Urology 2005, 5:18 http://www.biomedcentral.com/1471-2490/5/18
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Combining all information on 50 mg and 100 mg with
dose optimised regimens, particular adverse events were
reported in 2600 to 6300 men, and were generally higher
with sildenafil than with placebo, except serious adverse
events, which were not different. NNH values varied
between 4.9 (4.2 to 6.0) for men reporting at least one
adverse event (49% of men taking sildenafil), to 18 (15 to
23) for men reporting dyspepsia. Headache was the most
commonly reported individual adverse event in 17% of
men taking sildenafil, followed by flushing reported in
13% and dyspepsia in 7.8%. The majority of trials
reported that adverse events were mostly mild or moder-
ate, and frequently transient.
Tadalafil
Results for continuous efficacy outcomes for tadalafil are
shown in Table 4. Average results for percentage successful
attempts at intercourse, for the erectile function domain
score, and for the change in the erectile function domain
score from baseline were consistently available for 20 mg
fixed dose, but there were 109 men or fewer using 10 mg
or less. Combined data for 10 mg and 20 mg fixed doses
are reported (10/20).
Results for dichotomous variables of efficacy and adverse
events are shown in Table 6. For efficacy, the NNT for
improved erections was 1.9 for both the 20 mg fixed dose
and combined 10 plus 20 mg analysis. Combining all
information on 10 mg and 20 mg, improved erections in
1651 men were reported in 75% of men on tadalafil and
24% on placebo (Figure 1). The NNT was 1.9 (95% confi-
dence interval 1.8 to 2.1).
Combining all information on 10 mg and 20 mg, both all
cause and lack of efficacy withdrawals reported in about
1400 men, were lower with tadalafil than with placebo,
with NNTp values of 15 (8.8 to 46) and 24 (14 to 69)
respectively. Adverse event withdrawals were higher with
tadalafil than with placebo, with an NNH of 52 (29 to
260).
Combining all information on 10 mg and 20 mg, particu-
lar adverse events were reported in 600 to 1800 men, and
were generally higher with tadalafil than with placebo,
except serious adverse events, which were not different,
and rhinitis, where there were few events. NNH values var-
ied between 4.6 (3.4 to 7.2) for men reporting at least one
adverse event (47% of men taking tadalafil), to 24 (18 to
38) for men reporting dyspepsia. Headache was the most
commonly reported individual adverse event in 13% of
men taking tadalafil, followed by dyspepsia reported in
10% and flushing in 4.8%. The majority of trials reported
that adverse events were mostly mild or moderate, and
frequently transient.
Vardenafil
Results for continuous efficacy outcomes for vardenafil
are shown in Table 4. Average results for percentage suc-
cessful attempts at intercourse, for the erectile function
domain score, and for the change in the erectile function
Results of percentage of men with improved erections in individual trials of sildenafil, tadalafil, and vardenafil Figure 1
Results of percentage of men with improved erections in individual trials of sildenafil, tadalafil, and vardenafil.
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domain score from baseline were consistently available
for the optimised dose, and for some trials with fixed
dose. Combined data for 10 mg and 20 mg fixed doses
and dose optimised regimens are reported (10/20).
Results for dichotomous variables of efficacy and adverse
events are shown in Table 7. The analysis combined dose
optimised regimens with the 20 mg fixed dose, since the
bulk of patients on dose optimised regimens were taking
20 mg.
For efficacy, the NNT for improved erections was the same
at 2.0 for all doses above 5 mg, demonstrating compara-
ble efficacy and justifying combining those doses. Com-
bining all information on 10 mg and 20 mg with dose
optimised regimens, improved erections in 2856 men
were reported in 71% of men on vardenafil and 22% on
placebo (Figure 1). The NNT was 2.0 (95% confidence
interval 1.9 to 2.2).
Combining all information on 10 mg and 20 mg with
dose optimised regimens, both all cause and lack of effi-
cacy withdrawals reported in about 500 to 2300 men,
were lower with vardenafil than with placebo, with NNTp
values of 7.7 (6.0 to 11) and 11 (9.0 to 16) respectively.
Adverse event withdrawals, reported in about 2800 men,
were higher with vardenafil than with placebo, with an
NNH of 65 (37 to 250).
Combining all information on 10 mg and 20 mg with
dose optimised regimens, adverse event outcomes were
reported in 1000 to 2400 men, and were generally higher
with vardenafil than with placebo, except serious adverse
events, which were not different, and men with at least
one adverse event, which was not commonly reported in
these trials. The lowest (worst) NNH was 8.0 (6.9 to 9.6)
for men reporting flushing. Headache was the most com-
monly reported individual adverse event in 15% of men
taking vardenafil, followed by flushing reported in 13%
Table 5: Summary of dichotomous outcomes for sildenafil
Number of Percent with
Outcome Dose (mg) Trials Patients Sildenafil Placebo Relative 
benefit or 
risk (95% CI)
NNT/NNTp/
NNH (95% CI)
Efficacy
Improved 
erections
25 5 778 68 27 2.5 (2.1 to 3.0) 2.4 (2.1 to 2.9)
50 5 781 80 27 3.0 (2.5 to 3.5) 1.9 (1.7 to 2.1)
100 26 5000 76 23 3.4 (3.1 to 3.6) 1.9 (1.8 to 2.0)
50/100 29 5467 76 23 3.3 (3.1 to 3.5) 1.9 (1.8 to 2.0)
Withdrawal
All-cause 25 3 522 11 14 0.9 (0.6 to 1.4) not calculated
50 4 560 10 14 0.7 (0.4 to 1.2) not calculated
100 27 5219 7.8 12 0.6 (0.5 to 0.8) 22 (16 to 34)
50/100 30 5562 8.0 12 0.7 (0.6 to 0.8) 23 (17 to 37)
Lack of efficacy 25 3 522 3.0 3.7 0.9 (0.3 to 2.5) not calculated
50 3 526 1.8 3.5 0.6 (0.2 to 1.9) not calculated
100 27 5119 1.1 4.5 0.3 (0.2 to 0.4) 24 (20 to 32)
50/100 30 5463 1.2 4.4 0.3 (0.2 to 0.4) 25 (21 to 34)
Adverse event 25 4 777 1.5 1.3 1.0 (0.4 to 3.0) not calculated
50 5 819 1.6 1.2 1.7 (0.7 to 4.4) not calculated
100 28 5311 1.4 0.6 1.8 (1.1 to 2.7) 120 (66 to 520)
50/100 31 5787 1.6 0.6 1.7 (1.1 to 2.6) 120 (67 to 560)
Adverse events
All cause 50/100 18 2852 50 30 1.6 (1.5 to 1.8) 4.9 (4.2 to 6.0)
Serious 50/100 17 2591 2.5 2.4 1.1 (0.6 to 1.7) not calculated
Headache 50/100 34 6386 17 5.2 3.3 (2.8 to 3.9) 8.6 (7.6 to 10)
Dyspepsia 50/100 26 4967 7.8 2.3 3.3 (2.5 to 4.4) 18 (15 to 23)
Flushing 50/100 33 6363 13 1.9 6.7 (5.2 to 8.7) 9.0 (8.1 to 10)
Rhinitis 50/100 21 4283 5.4 2.1 2.5 (1.8 to 3.5) 31 (23 to 47)
NNT is given in standard font, NNTp in bold, and NNH in bold italic. No NNT/NNTp/NNH was calculated unless there was a statistically 
significant differenceBMC Urology 2005, 5:18 http://www.biomedcentral.com/1471-2490/5/18
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and rhinitis in 7.9%. The majority of trials reported that
adverse events were mostly mild or moderate, and fre-
quently transient.
Comparing different treatments
Continuous outcomes are compared in Table 8, which
documents the number of trials and patients for which the
consistently reported outcomes were available, together
with the weighted mean result for both placebo and the
top doses plus dose optimised regimens of individual
PDE-5 inhibitors. There was remarkable consistency. For
instance, the percentage of successful attempts at inter-
course with placebo varied narrowly between 23% and
28%. The three PDE-5 inhibitors had success rates of 65%
for sildenafil, 62% for tadalafil and 59% for vardenafil
(Figure 2). The final erectile function domain score, and
change from baseline were highly consistent for both pla-
cebo and PDE-5 inhibitors.
Dichotomous outcomes are compared in Table 9, docu-
menting the number of trials and patients for which the
consistently reported outcomes were available, together
with event rates for PDE-5 inhibitor and placebo, and the
NNT/NNTp/NNH values obtained. For efficacy, using
improved erections as the outcome, there was a high
degree of consistency for placebo with rates between 22%
and 24%. The three PDE-5 inhibitors had event rates of
76% for sildenafil, 75% for tadalafil and 71% for vardena-
fil (Figure 2). NNTs for all three PDE-5 inhibitors were 1.9
or 2.0.
There was much less consistency for information on with-
drawals. For instance, all cause and lack of efficacy with-
drawals were considerably higher with placebo in
vardenafil trials (32% and 12%) than with sildenafil trials
(12% and 4.4%), with tadalafil intermediate between
them. A similar gradient occurred for all cause (Figure 2)
and lack of efficacy withdrawals with PDE-5 inhibitors,
resulting in lower (better) NNTp values with vardenafil
and tadalafil than sildenafil because of these higher abso-
lute rates. Adverse event withdrawals were actually lower
with sildenafil than with tadalafil or vardenafil.
Event rates for particular adverse events tended to be con-
sistent between the PDE-5 inhibitor studies, with minor
differences. About half the men reported at least one
adverse event, though serious adverse events never
occurred more frequently with PDE-5 inhibitor than with
placebo. Headache was consistently the most commonly
reported individual adverse event. Flushing, dyspepsia, or
rhinitis/nasal congestion were also common, though with
different rates occurring with different PDE-5 inhibitors.
Other adverse events
Other adverse events were reported inconsistently. Back
pain and myalgia or increased CPK levels were mentioned
consistently in tadalafil studies, but neither of the other
Table 6: Summary of dichotomous outcomes for tadalafil
Number of Percent with
Outcome Dose (mg) Trials Patients Tadalafil Placebo Relative 
benefit or risk 
(95% CI)
NNT/NNTp/
NNH(95% CI)
Efficacy
Improved 
erections
10 2 215 64 23 2.8 (1.9 to 4.2) 2.4 (1.9 to 3.4)
20 7 1542 76 24 3.1 (2.7 to 3.7) 1.9 (1.7 to 2.1)
10/20 7 1651 75 24 3.1 (2.6 to 3.7) 1.9 (1.8 to 2.1)
Withdrawal
All-cause 10/20 5 1334 13 19 0.7 (0.5 to 0.9) 15 (8.8 to 46)
Lack of efficacy 10/20 6 1435 3.3 7.5 0.5 (0.3 to 0.7) 24 (14 to 69)
Adverse event 10/20 7 1657 3.4 1.5 2.3 (1.1 to 5.1) 52 (29 to 260)
Adverse events
All cause 10/20 3 590 47 25 1.8 (1.4 to 2.3) 4.6 (3.4 to 7.2)
Serious 10/20 7 1655 1.2 1.1 1.0 (0.4 to 2.8) not calculated
Headache 10/20 7 1810 13 3.4 3.5 (2.2 to 5.4) 11 (8.5 to 14)
Dyspepsia 10/20 6 1401 10 0.2 12 (4.3 to 35) 11 (8.8 to 14)
Flushing 10/20 6 1530 4.8 0.2 7.2 (2.5 to 20) 24 (18 to 38)
Rhinitis 10/20 2 712 3.1 0.5 4.5 (0.8 to 24) not calculated
NNT is given in standard font, NNTp in bold, and NNH in bold italic. No NNT/NNTp/NNH was calculated unless there was a statistically 
significant differenceBMC Urology 2005, 5:18 http://www.biomedcentral.com/1471-2490/5/18
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PDE-5 inhibitors (Table 3). Other adverse events ('flu syn-
drome, limb pain, CV events, fatigue, priapism, and nau-
sea) were reported on in only a small minority of men in
trials. Whether visual disturbances occurred was recorded
for a large proportion of men, but not in consistent terms,
limiting the ability to pool data. Most studies reported
that visual disturbances were uncommon.
Relationship between dosing and intercourse
There was generally no information on intervals between
dosing and timing of intercourse, either for speed of onset
of effect or duration of effect. Table 10 shows the only
consistent information concerning timing of intercourse,
from four studies [58,59,61,63] comparing tadalafil 20
mg with placebo. The majority of attempts and successful
attempts occurred within four hours, and about 90%
within 12 hours. Success rates with tadalafil 20 mg and
placebo did not differ, whatever time intercourse
occurred. No other studies provided useful information
relating to timing of intercourse after dosing.
Discussion
This analysis comprised 50 randomised comparisons of
PDE-5 inhibitors with placebo, in more than 12,000 men.
Trials included were all randomised and double blind,
and almost all (47/50) were of sufficiently high quality
(score of 3 or more out of 5) to avoid major known
sources of bias [73].
There was no direct comparison between one PDE-5
inhibitor and another that satisfied our inclusion criteria.
Three studies did make a direct comparison between
sildenafil and tadalafil, with no placebo. They are not
included in the analysis because one [74] was open,
another [75] was not convincingly double-blind, and the
third [76] used only four tablets per patient. All three stud-
ies looked at duration of effect, and two looked at patient
preferences. In these less than adequate trials, both drugs
seem to be equally effective up to 12 hours after dosing,
and both drugs were well tolerated.
Table 7: Summary of dichotomous outcomes for vardenafil
Number of Percent with
Outcome Dose (mg) Trials Patients Vardenafil Placebo Relative 
benefit or 
risk (95% CI)
NNT/NNTp/
NNH(95%CI)
Efficacy
Improved 
erections
5 3 833 62 27 2.3 (1.9 to 2.7) 2.9 (2.4 to 3.5)
10 5 1401 68 21 3.3 (2.9 to 3.9) 2.1 (1.9 to 2.3)
20 7 2147 73 22 3.4 (3.0 to 3.8) 2.0 (1.8 to 2.1)
10/20 7 2856 71 22 3.3 (3.0 to 3.8) 2.0 (1.9 to 2.2)
Withdrawal
All-cause 10 3 812 4.2 2.5 1.7 (0.8 to 3.7) not calculated
20 5 1623 18 32 0.6 (0.5 to 0.7) 6.9 (5.4 to 9.7)
10/20 5 2061 20 32 0.6 (0.5 to 0.6) 7.7 (6.0 to 11)
Lack of efficacy 5 2 505 11 18 0.6 (0.4 to 0.9) 14 (7.5 to 85)
10 4 1084 4 15 0.3 (0.2 to 0.4) 9.3 (7.1 to 14)
20 6 1831 4 13 0.3 (0.2 to 0.4) 11 (8.7 to 15)
10/20 6 2320 4 12 0.3 (0.2 to 0.4) 11 (9.0 to 16)
Adverse event 5 3 812 4.2 2.5 1.7 (0.8 to 3.7) not calculated
10 5 1395 2.8 1.9 1.5 (0.7 to 3.0) not calculated
20 7 2161 3.6 1.8 2.1 (1.2 to 5.3) 54 (31 to 210)
10/20 7 2868 3.3 1.8 1.8 (1.1 to 3.0) 65 (37 to 250)
Adverse events
All cause 10/20 insufficient data
Severe 10/20 3 1096 2.7 2.2 1.2 (0.5 to 2.8) not calculated
Serious 10/20 5 1984 2.2 3.2 0.7 (0.4 to 1.2) not calculated
Headache 10/20 6 2411 15 4.1 3.4 (2.4 to 4.8) 9.6 (7.9 to 12)
Dyspepsia 10/20 5 1972 3.8 0.3 7.3 (2.4 to 22) 31 (22 to 48)
Flushing 10/20 5 1984 13 0.8 13 (6.3 to 27) 8.0 (6.9 to 9.6)
Rhinitis 10/20 5 2212 7.9 3.6 2.2 (1.5 to 3.4) 23 (16 to 42)
NNT is given in standard font, NNTp in bold, and NNH in bold italic. No NNT/NNTp/NNH was calculated unless there was a statistically 
significant differenceBMC Urology 2005, 5:18 http://www.biomedcentral.com/1471-2490/5/18
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Published reports of three PDE-5 inhibitors for treatment
of male erectile dysfunction, while largely similar, had
interesting differences. These were principally in the
underlying aetiology of erectile dysfunction, regions of
the world where studies were performed, and in exclusion
criteria used to select men for the individual trials. Silde-
nafil was studied in 10 different clinical conditions, com-
pared with only three for tadalafil and vardenafil (Table
1). The only condition missing for sildenafil was after
prostatectomy, where studies could not be included
because they were not randomised. Most studies were per-
formed in North America and Europe (Table 2), though
sildenafil was studied in men in every inhabited conti-
nent, with 27% of men studied being in Asia, South Amer-
ica, or Africa.
Perhaps the most obvious difference between trials of dif-
ferent drugs was the use of different exclusion criteria in
individual studies. Five of eight tadalafil studies, and six of
seven vardenafil studies excluded men previously unre-
sponsive to PDE-5 inhibitors, thus permitting enrolment
to be enriched by responders compared with sildenafil
studies, in which such an exclusion would not have been
used because it was the first available PDE-5 inhibitor. It
is not clear how this major difference might have affected
the measured performance of the drugs. Exclusion of non-
responders to other PDE-5 inhibitors might be expected
to enhance the measured performance of any other PDE-
5 inhibitor under test, making it look better in indirect
comparisons. However, one vardenafil study including
men previously unresponsive to sildenafil [70] was not
greatly different from those overall.
The other major difference was in the reporting of out-
comes of studies, which varied greatly between the three
PDE-5 inhibitors. Common outcomes were responses to a
global question about improved erections ("Has the treat-
ment you have been taking over the past four weeks
improved your erections?"), and scores and change in
score for the erectile function domain. Some outcomes
were frequently reported in trials of one treatment, but
not others. For example, final scores and changes from
Summary of percentage of successful attempts at intercourse  (Successful), percentage of men with improved erections  (Improved), and of all-cause withdrawals (Withdrawals) for  top doses of sildenafil, tadalafil and vardenafil Figure 2
Summary of percentage of successful attempts at intercourse 
(Successful), percentage of men with improved erections 
(Improved), and of all-cause withdrawals (Withdrawals) for 
top doses of sildenafil, tadalafil and vardenafil.
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Table 8: Comparison of continuous efficacy results for sildenafil, tadalafil, and vardenafil
Sildenafil (50/100 mg) Tadalafil (10/20 mg) Vardenafil (10/20 mg)
Number of Number of Number of
Outcome Dose Trials Patients Weighted 
mean
Dose Trials Patients Weighted 
mean
Dose Trials Patients Weighted 
mean
Percentage 
successful 
attempts
placebo 16 1448 23 placebo 6 388 26 placebo 7 996 28
50/100 16 1589 65 10/20 6 1047 62 10/20 7 1789 59
Erectile 
function 
domain 
score
placebo 23 1870 14.0 placebo 6 388 14.6 placebo 7 996 14.0
50/100 23 1893 22.0 10/20 6 1047 22.3 10/20 7 1789 20.1
EF domain 
change
placebo 23 1870 2.7 placebo 7 459 0.8 placebo 7 996 1.3
50/100 23 1893 10.1 10/20 7 1192 8.4 10/20 7 1344 8.3B
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Table 9: Comparison of dichotomous efficacy results for sildenafil, tadalafil, and vardenafil
Sildenafil (50/100 mg) Tadalafil (10/20 mg) Vardenafil (10/20 mg)
Number of Percent with Number of Percent with Number of Percent with
Outcome Trials Patients Sildenafil Placebo NNT/
NNTp/
NNH 
(95% CI)
Trials Patients Tadalafil Placebo NNT/
NNTp/
NNH 
(95% CI)
Trials Patients Vardenafil Placebo NNT/
NNTp/
NNH 
(95% CI)
Efficacy
Improved 
erections
29 5467 76 23 1.9 
(1.8 to 2.0)
7 1651 75 24 1.9 
(1.8 to 2.1)
72 8 5 6 7 1 2 2 2 . 0  
(1.9 to 2.2)
Withdrawal
All-cause 30 5562 8 12 23 
(17 to 37)
5 1334 13 19 15 
(8.8 to 46)
52 0 6 1 2 0 3 2 7.7 
(6.0 to 11)
Lack of efficacy 30 5463 1.2 4.4 25 
(21 to 34)
6 1435 3.3 7.5 24 
(14 to 69)
62 3 2 0 4 . 0 1 2 11 
(9.0 to 16)
Adverse event 31 5787 1.6 0.6 120 
(67 to 560)
7 1657 3.4 1.5 52 
(29 to 260)
7 2868 3.3 1.8 65 
(37 to 250)
Adverse 
events
All cause 18 2862 50 30 4.9 
(4.2 to 6.0)
3 590 47 25 4.6 
(3.4 to 7.2)
insufficient data
Serious 17 2591 2.5 2.4 not 
calculated
7 1655 1.2 1.1 not 
calculated
5 1984 2.2 3.2 not 
calculated
Headache 34 6386 17 5.2 8.6 
(7.6 to 10)
7 1810 13 3.4 11 
(8.5 to 14)
62 4 1 1 1 5 4 . 1 9.6 
(7.9 to 12)
Dyspepsia 26 4967 7.8 2.3 18 
(15 to 23)
6 1401 10 0.2 11 
(8.8 to 14)
5 1972 3.8 0.3 31 
(22 to 48)
Flushing 33 6363 13 1.9 9.0 
(8.1 to 10)
6 1530 4.8 0.2 24 
(18 to 38)
51 9 8 4 1 3 0 . 8 8.0 
(6.9 to 9.6)
Rhinitis 21 4283 5.4 2.1 31 
(23 to 47)
2 712 3.1 0.5 not 
calculated
5 2212 7.9 3.6 23 
(16 to 42)
NNT is given in standard font, NNTp in bold, and NNH in bold italic. No NNT/NNTp/NNH was calculated unless there was a statistically significant differenceBMC Urology 2005, 5:18 http://www.biomedcentral.com/1471-2490/5/18
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baseline for IIEF questions 3 and 4, were reported for most
sildenafil, but not tadalafil or vardenafil trials.
There were clear differences in the philosophy of reporting
of efficacy and harm, principally between the first PDE-5
inhibitor sildenafil, and the subsequent ones, tadalafil
and vardenafil (Table 3). We could find no explanation
for this, nor any philosophical discussion about the clini-
cal and practical importance of different outcomes. Few
studies provided an estimate of how many men had an
outcome approximating erections sufficiently rigid for
penetration followed by successful intercourse. This sim-
ple pragmatic outcome is more relevant to affected men,
their partners, and their professional advisers than an
average movement on a scale like IIEF, which itself com-
prises a number of different questions. Useful outcomes,
like the number of men in whom the proportion of suc-
cessful attempts at sexual intercourse was more than 40%,
or 60% or more, known to be recorded in clinical trial
reports for sildenafil [6], were almost never reported in
published papers. Incomplete reporting of efficacy out-
comes has been reported before, for chronic [4] and acute
[77] pain.
Withdrawal from studies for any cause, because of lack of
effect, or because of adverse events was commonly
reported, while numbers of men with at least one adverse
event and occurrence of severe adverse events, was
recorded for a minority of trials. Serious adverse events
were recorded more frequently in tadalafil and vardenafil
trials than sildenafil trials, perhaps reflecting recency of
studies. The use of a cut-off level for reporting individual
adverse events limited the available information for these
outcomes.
Analysis of the individual PDE-5 inhibitors (Tables 4, 5, 6,
7) showed that the two top doses (including dose-optimi-
sation schedules) had very similar efficacy for all three
interventions. This consistency justified pooling informa-
tion from the two top doses.
Using this strategy to compare the three PDE-5 inhibitors
demonstrated remarkable consistency between them on
the basis of available data for any commonly reported
outcome. Absolute rates for placebo varied little, showing
no major difference between patients studied. The only
exception to this was for withdrawals, where tadalafil and
vardenafil studies had higher withdrawal rates with pla-
cebo and PDE-5 inhibitor than did sildenafil. There was
no obvious reason for this. It was perhaps surprising that
sildenafil compared well with tadalafil and vardenafil
given the much greater number of conditions studied, the
wider geographical spread, and that tadalafil and vardena-
fil studies used a form of enriched enrolment. Overall,
sildenafil offered most information, and a trend towards
better efficacy and lower adverse events.
How useful is this method of indirect comparison of
equivalent doses of PDE-5 inhibitors? It is clearly superior
to examining the little inadequate information on direct
comparison, and to any superficial examination of indi-
vidual trials, subject, as each will be, to the random play
of chance [13]. Large collections of data from high quality,
valid, trials are less subject to the vagaries of chance than
smaller individual studies. Large direct comparisons may
be better, but the evidence is that when large amounts of
trial data exist, direct comparisons give no different result
from indirect comparisons [1]. Further investigation of
differences between comparable doses would require
access to detailed clinical trial reports to report outcomes
available but not published.
More important than direct or indirect comparison of dif-
ferent PDE-5 inhibitors is the question of utility of out-
Table 10: Relationship of dosing to time and success of intercourse for tadalafil 20 mg and placebo in four trials
Time after dose (hours)
Outcome <0.5 to 4 >4 to 12 >12 to 24 >24 to 36
Percent of total attempts at intercourse
Placebo 75 15 9.0 1.7
Tadalafil 20 mg 61 23 12 3.7
Percent of successful attempts at intercourse
Placebo 74 15 8.4 3.3
Tadalafil 20 mg 60 23 13 4
Percent of attempts that were successful
P l a c e b o 2 62 62 45 0
Tadalafil 20 mg 65 68 72 74BMC Urology 2005, 5:18 http://www.biomedcentral.com/1471-2490/5/18
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comes. With over 12,000 men in clinical trials over a
decade, it is surprising that we have no consensus of what
is a useful outcome, and how a useful outcome is
reported. Individual patient analysis of clinical trial data
illustrates how standard trials could be better reported
[6,77], and this has already been done for PDE-5 inhibi-
tors [6].
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